KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Acquisitions (2023 - 2025)

Regeneron Pharmaceuticals has reported Acquisitions over the past 3 years, most recently at $300000.0 for Q4 2025.

  • Quarterly results put Acquisitions at $300000.0 for Q4 2025, down 97.39% from a year ago — trailing twelve months through Dec 2025 was $14.8 million (down 77.71% YoY), and the annual figure for FY2025 was $3.3 million, down 80.0%.
  • Acquisitions for Q4 2025 was $300000.0 at Regeneron Pharmaceuticals, down from $3.0 million in the prior quarter.
  • Over the last five years, Acquisitions for REGN hit a ceiling of $51.1 million in Q3 2023 and a floor of $300000.0 in Q4 2025.
  • Median Acquisitions over the past 3 years was $3.8 million (2023), compared with a mean of $13.9 million.
  • Biggest five-year swings in Acquisitions: skyrocketed 202.63% in 2024 and later tumbled 97.39% in 2025.
  • Regeneron Pharmaceuticals' Acquisitions stood at $3.8 million in 2023, then skyrocketed by 202.63% to $11.5 million in 2024, then tumbled by 97.39% to $300000.0 in 2025.
  • The last three reported values for Acquisitions were $300000.0 (Q4 2025), $3.0 million (Q3 2025), and $11.5 million (Q4 2024) per Business Quant data.